{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:39:33Z","timestamp":1788352773414,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.canlet.2022.215591","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T11:28:54Z","timestamp":1649330934000},"page":"215591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer"],"prefix":"10.1016","volume":"537","author":[{"given":"Shrey","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuwan","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Lavania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrishketan","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-1634","authenticated-orcid":false,"given":"Nikita S.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Dudeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.canlet.2022.215591_bib2","first-page":"318","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.canlet.2022.215591_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.canlet.2022.215591_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215591_bib5","article-title":"Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the Province of British Columbia: a Population-based retrospective study","author":"Ho","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215591_bib6","article-title":"Eligibility of metastatic pancreatic cancer patients for first-line Palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX","author":"Peixoto","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1517\/14656566.3.6.755","article-title":"Paclitaxel in cancer therapy","volume":"3","author":"Mekhail","year":"2002","journal-title":"Expet Opin. Pharmacother."},{"issue":"11","key":"10.1016\/j.canlet.2022.215591_bib8","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-induced cell death: where the cell cycle and apoptosis come together","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2022.215591_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0305-7372(93)90010-O","article-title":"The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere)","volume":"19","author":"Pazdur","year":"1993","journal-title":"Cancer Treat Rev."},{"issue":"3","key":"10.1016\/j.canlet.2022.215591_bib10","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0002-9440(10)63470-0","article-title":"Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers","volume":"163","author":"Masuda","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.661.3.6","article-title":"Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells","volume":"3","author":"Lee","year":"2004","journal-title":"Mol. Cancer Therapeut."},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib12","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/0008-5472.CAN-03-2013","article-title":"Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint","volume":"64","author":"Sudo","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.canlet.2022.215591_bib13","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1535-7163.MCT-06-0319","article-title":"Spindle checkpoint function and cellular sensitivity to antimitotic drugs","volume":"5","author":"Yamada","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib14","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1074\/jbc.M110295200","article-title":"Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors","volume":"277","author":"Kasai","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.canlet.2022.215591_bib15","doi-asserted-by":"crossref","first-page":"9407","DOI":"10.1158\/0008-5472.CAN-07-1077","article-title":"Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70","volume":"67","author":"Phillips","year":"2007","journal-title":"Cancer Res."},{"issue":"156","key":"10.1016\/j.canlet.2022.215591_bib16","doi-asserted-by":"crossref","first-page":"156ra39","DOI":"10.1126\/scitranslmed.3004334","article-title":"A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer","volume":"4","author":"Chugh","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"suppl 4S","key":"10.1016\/j.canlet.2022.215591_bib17","doi-asserted-by":"crossref","first-page":"TPS472","DOI":"10.1200\/jco.2016.34.4_suppl.tps472","article-title":"Phase I dose escalation and pharmokinetic study of a modified schedule of 14-o-phosphonooxymethyltriptolide","volume":"34","author":"Edward Greeno","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15 Suppl","key":"10.1016\/j.canlet.2022.215591_bib18","article-title":"Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide","volume":"75","author":"Greeno","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11605-015-3000-3","article-title":"Minnelide overcomes oxaliplatin resistance by downregulating the DNA repair pathway in pancreatic cancer","volume":"20","author":"Modi","year":"2016","journal-title":"J. Gastrointest. Surg."},{"issue":"5","key":"10.1016\/j.canlet.2022.215591_bib20","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3892\/ol.2016.4379","article-title":"Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells","volume":"11","author":"Qiao","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2022.215591_bib21","author":"Edward Greeno"},{"issue":"2","key":"10.1016\/j.canlet.2022.215591_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2010.04.046","article-title":"Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways","volume":"139","author":"Mujumdar","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11605-015-2985-y","article-title":"A novel immunocompetent mouse model of pancreatic cancer with robust stroma: a valuable tool for preclinical evaluation of new therapies","volume":"20","author":"Majumder","year":"2016","journal-title":"J. Gastrointest. Surg."},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib24","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2013.01.070","article-title":"Relevance of animal models of pancreatic cancer and pancreatitis to human disease","volume":"144","author":"Saluja","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.canlet.2022.215591_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.canlet.2012.01.006","article-title":"Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo","volume":"319","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2022.215591_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.surg.2014.04.055","article-title":"Sorafenib and triptolide as combination therapy for hepatocellular carcinoma","volume":"156","author":"Alsaied","year":"2014","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/dna.2014.2356","article-title":"Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo","volume":"33","author":"Liu","year":"2014","journal-title":"DNA Cell Biol."},{"issue":"3","key":"10.1016\/j.canlet.2022.215591_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.juro.2014.09.007","article-title":"Synergistic antitumor effect of triptolide and Cisplatin in Cisplatin resistant human bladder cancer cells","volume":"193","author":"Ho","year":"2015","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/17474124.2014.925799","article-title":"Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer","volume":"8","author":"Borazanci","year":"2014","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"issue":"47","key":"10.1016\/j.canlet.2022.215591_bib31","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","article-title":"Mechanisms of Taxol resistance related to microtubules","volume":"22","author":"Orr","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215591_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4613-1267-3_6","article-title":"Paclitaxel (taxol): mechanisms of resistance","volume":"87","author":"Casazza","year":"1996","journal-title":"Cancer Treat Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/cmdc.200600308","article-title":"Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes","volume":"2","author":"Galletti","year":"2007","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.canlet.2022.215591_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1083\/jcb.200204048","article-title":"BubR1 is essential for kinetochore localization of other spindle checkpoint proteins and its phosphorylation requires Mad1","volume":"158","author":"Chen","year":"2002","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1083\/jcb.200306153","article-title":"Spindle checkpoint proteins Mad1 and Mad2 are required for cytostatic factor-mediated metaphase arrest","volume":"163","author":"Tunquist","year":"2003","journal-title":"J. Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2022.215591_bib37","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1091\/mbc.e02-04-0203","article-title":"Distinct chromosome segregation roles for spindle checkpoint proteins","volume":"13","author":"Warren","year":"2002","journal-title":"Mol. Biol. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrm3494","article-title":"Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore","volume":"14","author":"Foley","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2022.215591_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ccr.2005.06.011","article-title":"Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death","volume":"8","author":"Weaver","year":"2005","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.canlet.2022.215591_bib40","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.canlet.2022.215591_bib41","first-page":"3747","article-title":"Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide","volume":"31","author":"Fryer","year":"2011","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2022.215591_bib42","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1078-0432.CCR-07-2247","article-title":"Gemcitabine resistance in pancreatic cancer: picking the key players","volume":"14","author":"Kim","year":"2008","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.canlet.2022.215591_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jphs.2015.01.006","article-title":"Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors","volume":"127","author":"Minami","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2022.215591_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.172","article-title":"Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway","volume":"6","author":"Namba","year":"2015","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.canlet.2022.215591_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccr.2014.05.026","article-title":"Pancreatic cancer stroma: friend or foe?","volume":"25","author":"Gore","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.canlet.2022.215591_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.18632\/oncoscience.198","article-title":"Revisiting stroma in pancreatic cancer","volume":"2","author":"Khan","year":"2015","journal-title":"Oncoscience"},{"issue":"12","key":"10.1016\/j.canlet.2022.215591_bib47","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26788","article-title":"The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration","volume":"2","author":"Watt","year":"2013","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.canlet.2022.215591_bib48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/hpb.12334","article-title":"The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy","volume":"17","author":"Bever","year":"2015","journal-title":"HPB"},{"issue":"10","key":"10.1016\/j.canlet.2022.215591_bib49","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.cgh.2008.05.006","article-title":"The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma","volume":"6","author":"Erkan","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol. : the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.canlet.2022.215591_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0b013e3181dbf647","article-title":"Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma","author":"Fujita","year":"2010","journal-title":"Pancreas"},{"issue":"21","key":"10.1016\/j.canlet.2022.215591_bib51","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1158\/1078-0432.CCR-03-0825","article-title":"Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma","volume":"10","author":"Armstrong","year":"2004","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"2 Pt B","key":"10.1016\/j.canlet.2022.215591_bib52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.canlet.2014.10.020","article-title":"Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma","volume":"356","author":"Berchtold","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2022.215591_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-15-1155","article-title":"Impaired synthesis of stromal components in response to minnelide improves vascular function, drug delivery, and survival in pancreatic cancer","volume":"22","author":"Banerjee","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2022.215591_bib54","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3748\/wjg.v20.i9.2237","article-title":"Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies","volume":"20","author":"Rucki","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.canlet.2022.215591_bib55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.canlet.2022.215591_bib56","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/carcin\/bgt227","article-title":"Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer","volume":"34","author":"Awasthi","year":"2013","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.canlet.2022.215591_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1440-1746.1992.tb01030.x","article-title":"Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2)","volume":"7","author":"Iwamura","year":"1992","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.canlet.2022.215591_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/A:1011900818419","article-title":"High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice","volume":"18","author":"Kitamura","year":"2000","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2022.215591_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:03:18Z","timestamp":1759593798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":59,"alternative-id":["S0304383522000660"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215591","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"215591"}}